Nuvectis Pharma, Inc. NVCT
20.22
(1.41)
(6.52%)
as of 25 Sep
- Market cap
- $706.1M
- P/E
- 0.0×
Follow NVCT
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(158.88%) | (205.30%) | (168.24%) | (233.30%) | |
| (105.13%) | (114.76%) | (106.54%) | (122.61%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(115.81%) | (156.80%) | (208.08%) | (333.35%) | |
Free Cash Flow per Share |
(0.64) | (0.73) | (0.78) | (0.83) | |
Free Cash Flow |
(14.50) | (16.01) | (18.35) | (19.51) | |
Piotroski F-Score |
2.00 | 2.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(24.39%) | (31.99%) | (46.62%) | (62.45%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.52 | 0.55 | 0.62 | 0.64 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.64) | (0.73) | (0.78) | (0.83) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates